Béo phì và các biến chứng chuyển hóa: Vai trò của Adipokine và mối quan hệ giữa béo phì, viêm, kháng insulin, rối loạn lipid máu và bệnh gan nhiễm mỡ không do rượu

Available online: http://www.who.int/mediacentre/factsheets/fs311/en/.

Wang, 2011, Health and economic burden of the projected obesity trends in the USA and the UK, Lancet, 378, 815, 10.1016/S0140-6736(11)60814-3

Arrese, 2014, The prevalence of nonalcoholic fatty liver disease in the Americas, Ann. Hepatol, 13, 166, 10.1016/S1665-2681(19)30879-8

Carr, 2004, Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome, Diabetes, 53, 2087, 10.2337/diabetes.53.8.2087

Xu, 2003, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J. Clin. Investig, 112, 1821, 10.1172/JCI200319451

Hotamisligil, 2006, Inflammation and metabolic disorders, Nature, 444, 860, 10.1038/nature05485

Lumeng, 2011, Inflammatory links between obesity and metabolic disease, J. Clin. Investig, 121, 2111, 10.1172/JCI57132

Kershaw, 2004, Adipose tissue as an endocrine organ, J. Clin. Endocrinol. Metab, 89, 2548, 10.1210/jc.2004-0395

Hauner, 2005, Secretory factors from human adipose tissue and their functional role, Proc. Nutr. Soc, 64, 163, 10.1079/PNS2005428

Halberg, 2008, The adipocyte as an endocrine cell, Endocrinol. Metab. Clin. N. Am, 37, 753, 10.1016/j.ecl.2008.07.002

Perseghin, 1997, Metabolic defects in lean nondiabetic offspring of NIDDM parents: A cross-sectional study, Diabetes, 46, 1001, 10.2337/diab.46.6.1001

Boden, 2008, Obesity and free fatty acids, Endocrinol. Metab. Clin. N. Am, 37, 635, 10.1016/j.ecl.2008.06.007

Horowitz, 1999, Effect of short-term fasting on lipid kinetics in lean and obese women, Am. J. Physiol, 276, E278

Large, 1999, Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects, J. Lipid Res, 40, 2059, 10.1016/S0022-2275(20)32429-9

Reynisdottir, 2000, Influence of heredity for obesity on adipocyte lipolysis in lean and obese subjects, Int. J. Obes. Relat. Metab. Disord, 24, 340, 10.1038/sj.ijo.0801134

McQuaid, 2011, Downregulation of adipose tissue fatty acid trafficking in obesity: A driver for ectopic fat deposition?, Diabetes, 60, 47, 10.2337/db10-0867

Langin, 2005, Adipocyte lipases and defect of lipolysis in human obesity, Diabetes, 54, 3190, 10.2337/diabetes.54.11.3190

Jocken, 2007, Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state, J. Clin. Endocrinol. Metab, 92, 2292, 10.1210/jc.2006-1318

Karpe, 2011, Fatty acids, obesity, and insulin resistance: Time for a reevaluation, Diabetes, 60, 2441, 10.2337/db11-0425

Hausman, 2001, The biology of white adipocyte proliferation, Obes. Rev, 2, 239, 10.1046/j.1467-789X.2001.00042.x

Spalding, 2008, Dynamics of fat cell turnover in humans, Nature, 453, 783, 10.1038/nature06902

Tchoukalova, 2010, Regional differences in cellular mechanisms of adipose tissue gain with overfeeding, Proc. Natl. Acad. Sci. USA, 107, 18226, 10.1073/pnas.1005259107

Wang, 2005, Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men, Am. J. Clin. Nutr, 81, 555, 10.1093/ajcn/81.3.555

Kim, 2007, Obesity-associated improvements in metabolic profile through expansion of adipose tissue, J. Clin. Investig, 117, 2621, 10.1172/JCI31021

Weyer, 2000, Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance, Diabetologia, 43, 1498, 10.1007/s001250051560

Boden, 1997, Role of fatty acids in the pathogenesis of insulin resistance and NIDDM, Diabetes, 46, 3, 10.2337/diab.46.1.3

Kelley, 1993, Interaction between glucose and free fatty acid metabolism in human skeletal muscle, J. Clin. Investig, 92, 91, 10.1172/JCI116603

Shi, 2006, TLR4 links innate immunity and fatty acid-induced insulin resistance, J. Clin. Investig, 116, 3015, 10.1172/JCI28898

Suganami, 2005, A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha, Arterioscler. Thromb. Vasc. Biol, 25, 2062, 10.1161/01.ATV.0000183883.72263.13

Byrne, 1999, Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome, Diabet. Med, 16, 1007, 10.1046/j.1464-5491.1999.00184.x

Cho, 2012, Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice, Br. J. Nutr, 108, 2166, 10.1017/S0007114512000347

Charles, 2001, High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: Results from the paris prospective study, Am. J. Epidemiol, 153, 292, 10.1093/aje/153.3.292

Reeds, 2006, Adipose tissue, hepatic, and skeletal muscle insulin sensitivity in extremely obese subjects with acanthosis nigricans, Metabolism, 55, 1658, 10.1016/j.metabol.2006.08.006

Jernas, 2006, Separation of human adipocytes by size: Hypertrophic fat cells display distinct gene expression, FASEB J, 20, 1540, 10.1096/fj.05-5678fje

Skurk, 2007, Relationship between adipocyte size and adipokine expression and secretion, J. Clin. Endocrinol. Metab, 92, 1023, 10.1210/jc.2006-1055

Hotamisligil, 1993, Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance, Science, 259, 87, 10.1126/science.7678183

Amrani, 1996, Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage, J. Endocrinol, 148, 139, 10.1677/joe.0.1480139

Sartipy, 2003, Monocyte chemoattractant protein 1 in obesity and insulin resistance, Proc. Natl. Acad. Sci. USA, 100, 7265, 10.1073/pnas.1133870100

Rotter, 2003, Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects, J. Biol. Chem, 278, 45777, 10.1074/jbc.M301977200

Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J. Clin. Investig, 112, 1796, 10.1172/JCI200319246

Lumeng, 2007, Obesity induces a phenotypic switch in adipose tissue macrophage polarization, J. Clin. Investig, 117, 175, 10.1172/JCI29881

Jiao, 2009, Obesity-related upregulation of monocyte chemotactic factors in adipocytes: Involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways, Diabetes, 58, 104, 10.2337/db07-1344

Lee, 2014, Exploring the activated adipogenic niche: Interactions of macrophages and adipocyte progenitors, Cell Cycle, 13, 184, 10.4161/cc.27647

Nomiyama, 2007, Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice, J. Clin. Investig, 117, 2877, 10.1172/JCI31986

Weisberg, 2006, CCR2 modulates inflammatory and metabolic effects of high-fat feeding, J. Clin. Investig, 116, 115, 10.1172/JCI24335

Nara, 2007, Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance, J. Biol. Chem, 282, 30794, 10.1074/jbc.M700412200

Feng, 2011, Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice, PLoS One, 6, e24358, 10.1371/journal.pone.0024358

Viguerie, 2004, Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects, FASEB J, 18, 1657, 10.1096/fj.04-2204com

Cancello, 2005, Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss, Diabetes, 54, 2277, 10.2337/diabetes.54.8.2277

Schipper, 2012, Adipose tissue-resident immune cells: Key players in immunometabolism, Trends. Endocrinol. Metab, 23, 407, 10.1016/j.tem.2012.05.011

Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem. Biophys. Res. Commun, 257, 79, 10.1006/bbrc.1999.0255

Lillioja, 1993, Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus, N. Engl. J. Med, 329, 1988, 10.1056/NEJM199312303292703

Kahn, 2000, Obesity and insulin resistance, J. Clin. Investig, 106, 473, 10.1172/JCI10842

Schenk, 2008, Insulin sensitivity: Modulation by nutrients and inflammation, J. Clin. Investig, 118, 2992, 10.1172/JCI34260

Holland, 2007, Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance, Cell Metab, 5, 167, 10.1016/j.cmet.2007.01.002

Dressler, 1992, Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system, Science, 255, 1715, 10.1126/science.1313189

Teruel, 2001, Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state, Diabetes, 50, 2563, 10.2337/diabetes.50.11.2563

Haus, 2009, Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance, Diabetes, 58, 337, 10.2337/db08-1228

Holland, 2011, Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice, J. Clin. Investig, 121, 1858, 10.1172/JCI43378

Horowitz, 2000, Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women, Am. J. Physiol. Endocrinol. Metab, 278, E1144, 10.1152/ajpendo.2000.278.6.E1144

Bajaj, 2005, Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients, Diabetes, 54, 3148, 10.2337/diabetes.54.11.3148

Santomauro, 1999, Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects, Diabetes, 48, 1836, 10.2337/diabetes.48.9.1836

Girousse, 2013, Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass, PLoS Biol, 11, e1001485, 10.1371/journal.pbio.1001485

Kosteli, 2010, Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue, J. Clin. Investig, 120, 3466, 10.1172/JCI42845

Apovian, 2008, Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects, Arterioscler. Thromb. Vasc. Biol, 28, 1654, 10.1161/ATVBAHA.108.170316

Anderson, 2010, Adipose tissue recruitment of leukocytes, Curr. Opin. Lipidol, 21, 172, 10.1097/MOL.0b013e3283393867

Fain, 2010, Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: A review, Mediat. Inflamm, 2010, 513948, 10.1155/2010/513948

Ouchi, 2011, Adipokines in inflammation and metabolic disease, Nat. Rev. Immunol, 11, 85, 10.1038/nri2921

Huber, 2008, CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity, J. Clin. Endocrinol. Metab, 93, 3215, 10.1210/jc.2007-2630

Deshmane, 2009, Monocyte chemoattractant protein-1 (MCP-1): An overview, J. Interferon Cytokine Res, 29, 313, 10.1089/jir.2008.0027

Kanda, 2006, MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity, J. Clin. Investig, 116, 1494, 10.1172/JCI26498

Kamei, 2006, Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance, J. Biol. Chem, 281, 26602, 10.1074/jbc.M601284200

Lumeng, 2008, Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes, Diabetes, 57, 3239, 10.2337/db08-0872

Meijer, 2011, Human primary adipocytes exhibit immune cell function: Adipocytes prime inflammation independent of macrophages, PLoS One, 6, e17154, 10.1371/journal.pone.0017154

Simeoni, 2004, Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus, Diabetologia, 47, 1574, 10.1007/s00125-004-1494-4

Karadeniz, 2010, Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy, Endocrine, 37, 513, 10.1007/s12020-010-9342-4

Jing, 2011, Monocyte chemoattractant protein 1–2518 A/G polymorphism and susceptibility to type 2 diabetes in a Chinese population, Clin. Chim. Acta, 412, 466, 10.1016/j.cca.2010.11.030

Zietz, 2005, Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the −2518 A→G promoter polymorphism, Diabetes Obes. Metab, 7, 570, 10.1111/j.1463-1326.2004.00436.x

Katakami, 2010, Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabetes, Diabetes Res. Clin. Pract, 89, e9, 10.1016/j.diabres.2010.04.006

Keophiphath, 2009, CCL5 promotes macrophage recruitment and survival in human adipose tissue, Arterioscler. Thromb. Vasc. Biol, 30, 39, 10.1161/ATVBAHA.109.197442

Chavey, 2009, CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance, Cell Metab, 9, 339, 10.1016/j.cmet.2009.03.002

Tourniaire, 2013, Chemokine Expression in Inflamed Adipose Tissue Is Mainly Mediated by NF-κB, PLoS One, 8, e66515, 10.1371/journal.pone.0066515

Ruan, 2003, Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-α, Cytokine Growth Factor Rev, 14, 447, 10.1016/S1359-6101(03)00052-2

Uysal, 1997, Protection from obesity-induced insulin resistance in mice lacking TNF-α function, Nature, 389, 610, 10.1038/39335

Miyazaki, 2003, Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients, Int. J. Obes. Relat. Metab. Disord, 27, 88, 10.1038/sj.ijo.0802187

Wascher, 2011, Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in “healthy” men with metabolic syndrome, Mol. Med, 17, 189, 10.2119/molmed.2010.00221

Bernstein, 2006, Effects of etanercept in patients with the metabolic syndrome, Arch. Intern. Med, 166, 902, 10.1001/archinte.166.8.902

McArdle, 2013, Mechanisms of obesity-induced inflammation and insulin resistance: Insights into the emerging role of nutritional strategies, Front. Endocrinol. (Lausanne), 4, 52, 10.3389/fendo.2013.00052

Illei, 2000, Novel, antigen-specific therapeutic approaches to autoimmuneinflammatory diseases, Curr. Opin. Immunol, 12, 712, 10.1016/S0952-7915(00)00167-9

Marino, 1998, Inhibition of interferon gamma induced interleukin 12 production—A potential mechanism for the anti-inflammatory activities of tumor necrosis factor, Proc. Natl. Acad. Sci. USA, 95, 13806, 10.1073/pnas.95.23.13806

White, 2012, Systemic inflammation and insulin sensitivity in obese IFN-γ knockout mice, Metabolism, 61, 1152, 10.1016/j.metabol.2012.01.018

Sultan, 2009, T cell-mediated inflammation in adipose tissue does not cause insulin resistance in hyperlipidemic mice, Circ. Res, 104, 961, 10.1161/CIRCRESAHA.108.190280

Ricart, 2003, Insulin resistance and chronic cardiovascular inflammatory syndrome, Endocr. Rev, 24, 278, 10.1210/er.2002-0010

Goodrick, 1997, Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha in vivo, J. Clin. Endocrinol. Metab, 82, 4196

Sopasakis, 2004, High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator, Obes. Res, 12, 454, 10.1038/oby.2004.51

Bastard, 2002, Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro, J. Clin. Endocrinol. Metab., 87, 2084, 10.1210/jcem.87.5.8450

Pradhan, 2001, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, JAMA, 286, 327, 10.1001/jama.286.3.327

Tsigos, 1997, Dose-dependent effects of recombinant human interleukin-6 on glucose regulation, J. Clin. Endocrinol. Metab, 82, 4167, 10.1210/jcem.82.12.4422

Wallenius, 2002, Interleukin-6-deficient mice develop mature-onset obesity, Nat. Med, 8, 75, 10.1038/nm0102-75

Hensley, 2004, Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: Absence of development of age-related obesity, Am. J. Physiol. Endocrinol. Metab, 287, E182, 10.1152/ajpendo.00189.2003

Starkie, 2003, Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans, FASEB J, 17, 884, 10.1096/fj.02-0670fje

Carey, 2006, Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase, Diabetes, 55, 2688, 10.2337/db05-1404

Wood, 2005, The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNFalpha in human adipocytes, Biochem. Biophys. Res. Commun, 337, 422, 10.1016/j.bbrc.2005.09.068

Esposito, 2002, Weight loss reduces interleukin-18 levels in obese women, J. Clin. Endocrinol. Metab, 87, 3864, 10.1210/jcem.87.8.8781

Tan, 2010, IL-18 overexpression promotes vascular inflammation and remodeling in a rat model of metabolic syndrome, Atherosclerosis, 208, 350, 10.1016/j.atherosclerosis.2009.07.053

Netea, 2006, Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance, Nat. Med, 12, 650, 10.1038/nm1415

Friedman, 1998, Leptin and the regulation of body weight in mammals, Nature, 395, 763, 10.1038/27376

Considine, 1996, Serum immunoreactive-leptin concentrations in normal-weight and obese humans, N. Engl. J. Med, 334, 292, 10.1056/NEJM199602013340503

Kouidhi, 2010, Relationship between subcutaneous adipose tissue expression of leptin and obesity in Tunisian patients, Tunis. Med, 88, 569

Gonzalez, 2012, Role of leptin in the pancreatic β-cell: Effects and signaling pathways, J. Mol. Endocrinol, 49, R9, 10.1530/JME-12-0025

Ertl, 1997, Leptin impairs metabolic actions of insulin in isolated rat adipocytes, J. Biol. Chem, 272, 10585, 10.1074/jbc.272.16.10585

Arribas, 2004, Leptin impairs insulin signaling in rat adipocytes, Diabetes, 53, 347, 10.2337/diabetes.53.2.347

Mastronardi, 2012, Leptin: Molecular mechanisms, systemic pro-inflammatory effects, and clinical implications, Arq. Bras. Endocrinol. Metabol, 56, 597, 10.1590/S0004-27302012000900001

Lord, 1998, Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression, Nature, 394, 897, 10.1038/29795

Grunfeld, 1996, Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters, J. Clin. Investig, 97, 2152, 10.1172/JCI118653

Satoh, 2004, Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats, J. Clin. Investig, 114, 224, 10.1172/JCI20785

Qi, 2006, Loss of resistin improves glucose homeostasis in leptin deficiency, Diabetes, 55, 3083, 10.2337/db05-0615

Banerjee, 2004, Regulation of fasted blood glucose by resistin, Science, 303, 1195, 10.1126/science.1092341

Steppan, 2005, Activation of SOCS-3 by resistin, Mol. Cell. Biol, 25, 1569, 10.1128/MCB.25.4.1569-1575.2005

2001, Resistin: A new link between obesity and insulin resistance?, Clin. Endocrinol, 55, 437, 10.1046/j.1365-2265.2001.01377.x

McTernan, 2002, Resistin, central obesity, and type 2 diabetes, Lancet, 359, 46, 10.1016/S0140-6736(02)07281-1

McTernan, 2002, Increased resistin gene and protein expression in human abdominal adipose tissue, J. Clin. Endocrinol. Metab, 87, 2407, 10.1210/jcem.87.5.8627

Wang, 2002, Human resistin gene: Molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians, J. Clin. Endocrinol. Metab, 87, 2520, 10.1210/jcem.87.6.8528

Osawa, 2004, The G/G genotype of a resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3, Am. J. Hum. Genet, 75, 678, 10.1086/424761

Kielstein, 2003, Increased resistin blood levels are not associated with insulin resistance in patients with renal disease, Am. J. Kidney Dis, 42, 62, 10.1016/S0272-6386(03)00409-8

Patel, 2003, Resistin is expressed in human macrophages and directly regulated by PPARγ activators, Biochem. Biophys. Res. Commun, 300, 472, 10.1016/S0006-291X(02)02841-3

Qatanani, 2009, Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice, J. Clin. Investig, 119, 531, 10.1172/JCI37273

Mertens, 2002, Obesity, haemostasis and the fibrinolytic system, Obes. Rev, 3, 85, 10.1046/j.1467-789X.2002.00056.x

Alessi, 2003, Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk, J. Thromb. Haemost, 1, 1575, 10.1046/j.1538-7836.2003.00279.x

Ma, 2004, Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1, Diabetes, 53, 336, 10.2337/diabetes.53.2.336

Liang, 2006, Plasminogen activator inhibitor-1 modulates adipocyte differentiation, Am. J. Physiol. Endocrinol. Metab, 290, E103, 10.1152/ajpendo.00605.2004

Xu, 2009, Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells, Exp. Lung Res, 35, 795, 10.3109/01902140902912519

Samal, 1994, Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor, Mol. Cell. Biol, 14, 1431

Fukuhara, 2005, Visfatin: A protein secreted by visceral fat that mimics the effects of insulin, Science, 307, 426, 10.1126/science.1097243

Revollo, 2007, Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme, Cell Metab, 6, 363, 10.1016/j.cmet.2007.09.003

Pagano, 2006, Reduced plasma visfatin/pre B-cell colony-enhancing factor in obesity is not related to insulin resistance in humans, J. Clin. Endocrinol. Metab, 91, 3165, 10.1210/jc.2006-0361

Berndt, 2005, Plasma visfatin concentrations and fat-depot specific mRNA expression in humans, Diabetes, 54, 2911, 10.2337/diabetes.54.10.2911

Fain, 2008, Identification of omentin mRNA in human epicardial adipose tissue: Comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots, Int. J. Obes, 32, 810, 10.1038/sj.ijo.0803790

Chang, 2010, The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids, Metabolism, 59, 93, 10.1016/j.metabol.2009.07.011

Haider, 2006, Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding, J. Clin. Endocrinol. Metab, 91, 1578, 10.1210/jc.2005-2248

Kassem, 2011, Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus, Metabolism, 60, 63, 10.1016/j.metabol.2010.04.008

Varma, 2007, Human visfatin expression: Relationship to insulin sensitivity, intramyocellular lipids, and inflammation, J. Clin. Endocrinol. Metab, 92, 666, 10.1210/jc.2006-1303

Kang, 2014, Central visfatin potentiates glucose-stimulated insulin secretion and β-cell mass without increasing serum visfatin levels in diabetic rats, Cytokine, 65, 159, 10.1016/j.cyto.2013.11.008

Oki, 2007, Circulating visfatin level is correlated with inflammation, but not with insulin resistance, Clin. Endocrinol, 67, 796, 10.1111/j.1365-2265.2007.02966.x

Quadro, 1999, Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein, EMBO J, 18, 4633, 10.1093/emboj/18.17.4633

Yang, 2005, Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes, Nature, 436, 356, 10.1038/nature03711

Graham, 2007, Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass, Cell Metab, 6, 79, 10.1016/j.cmet.2007.06.002

Ost, 2007, Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes, FASEB J, 21, 3696, 10.1096/fj.07-8173com

Graham, 2006, Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects, N. Engl. J. Med, 354, 2552, 10.1056/NEJMoa054862

Gavi, 2007, Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes, J. Clin. Endocrinol. Metab, 92, 1886, 10.1210/jc.2006-1815

Balagopal, 2007, Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: Association with subclinical inflammation, J. Clin. Endocrinol. Metab, 92, 1971, 10.1210/jc.2006-2712

Nair, 2010, Case-control analysis of SNPs in GLUT4, RBP4 and STRA6: Association of SNPs in STRA6 with type 2 diabetes in a South Indian population, PLoS One, 5, e11444, 10.1371/journal.pone.0011444

Munkhtulga, 2007, Identification of a regulatory SNP in the retinol binding protein 4 gene associated with type 2 diabetes in Mongolia, Hum. Genet, 120, 879, 10.1007/s00439-006-0264-4

Munkhtulga, 2010, Regulatory SNP in the RBP4 gene modified the expression in adipocytes and associated with BMI, Obesity, 18, 1006, 10.1038/oby.2009.358

Varma, 2007, Retinol binding protein 4 expression in humans: Relationship to insulin resistance, inflammation, and response to pioglitazone, J. Clin. Endocrinol. Metab, 92, 2590, 10.1210/jc.2006-0816

Ulgen, 2010, Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients, Arch. Physiol. Biochem, 116, 57, 10.3109/13813451003631421

Kos, 2011, Human RBP4 adipose tissue expression is gender specific and influenced by leptin, Clin. Endocrinol. (Oxf.), 74, 197, 10.1111/j.1365-2265.2010.03892.x

Tabata, 2009, Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance, Cell Metab, 10, 178, 10.1016/j.cmet.2009.08.003

Doi, 2013, Angiopoietin-like protein 2 and risk of type 2 diabetes in a general Japanese population: The Hisayama study, Diabetes Care, 36, 98, 10.2337/dc12-0166

Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat. Med, 7, 947, 10.1038/90992

Diez, 2003, The role of the novel adipocyte-derived hormone adiponectin in human disease, Eur. J. Endocrinol, 148, 293, 10.1530/eje.0.1480293

Kern, 2003, Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression, Diabetes, 52, 1779, 10.2337/diabetes.52.7.1779

Maeda, 2002, Diet-induced insulin resistance in mice lacking adiponectin/ACRP30, Nat. Med, 8, 731, 10.1038/nm724

Kadowaki, 2006, Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome, J. Clin. Investig, 116, 1784, 10.1172/JCI29126

Ouchi, 2010, Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity, Science, 329, 454, 10.1126/science.1188280

Hu, 2013, Plasma SFRP5 levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistance, Diabetes Res. Clin. Pract, 99, 391, 10.1016/j.diabres.2012.11.026

Hu, 2013, Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans, J. Clin. Endocrinol. Metab, 98, 290, 10.1210/jc.2012-2466

Tan, X., Wang, X., Chu, H., Liu, H., Yi, X., and Xiao, Y. (2013). SFRP5 correlates with obesity and metabolic syndrome and increases after weight loss in children. Clin. Endocrinol. (Oxf.).

Carstensen, 2013, Sfrp5 correlates with insulin resistance and oxidative stress, Eur. J. Clin. Investig, 43, 350, 10.1111/eci.12052

Saleh, 1999, Regulation of Plasma fatty acid metabolism, Clin. Chim. Acta, 286, 163, 10.1016/S0009-8981(99)00099-6

Tinahones, 2011, Adipose tissue gene expression of factors related to lipid processing in obesity, PLoS One, 6, e24783, 10.1371/journal.pone.0024783

Klop, 2012, A physician’s guide for the management of hypertriglyceridemia: The etiology of hypertriglyceridemia determines treatment strategy, Panminerva Med, 54, 91

Klop, 2013, Dyslipidemia in obesity: Mechanisms and potential targets, Nutrients, 5, 1218, 10.3390/nu5041218

Guendouzi, 1999, Biochemical and physical properties of remnant-HDL2 and of pre beta 1-HDL produced by hepatic lipase, Biochemistry, 38, 2762, 10.1021/bi9815086

Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin. Chem, 18, 499, 10.1093/clinchem/18.6.499

Contois, 2011, Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement, J. Clin. Lipidol, 5, 264, 10.1016/j.jacl.2011.05.004

Ito, 2011, Development of a homogeneous assay for measurement of small dense LDL cholesterol, Clin. Chem, 57, 57, 10.1373/clinchem.2010.149559

Cantin, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men, Arterioscler. Thromb. Vasc. Biol, 25, 553, 10.1161/01.ATV.0000154144.73236.f4

Rizzo, 2009, Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome, Clin. Endocrinol. (Oxf.), 70, 870, 10.1111/j.1365-2265.2008.03407.x

Engfeldt, 1988, Lipolysis in human adipocytes, effects of cell size, age and of regional differences, Horm. Metab. Res, 19, 26

Veilleux, 2011, Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women, Diabetes, 60, 1504, 10.2337/db10-1039

Sam, 2008, Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes, Diabetes, 57, 2022, 10.2337/db08-0157

Johnson, 2001, Impaired insulin action in subcutaneous adipocytes from women with visceral obesity, Am. J. Physiol. Endocrinol. Metab, 280, E40, 10.1152/ajpendo.2001.280.1.E40

Despres, 1989, Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women, Arteriosclerosis, 9, 485, 10.1161/01.ATV.9.4.485

Carr, 2001, The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity, J. Clin. Endocrinol. Metab, 86, 2831

Cancello, 2006, Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity, Diabetes, 55, 1554, 10.2337/db06-0133

Esteve, 2005, Dyslipidemia and inflammation: An evolutionary conserved mechanism, Clin. Nutr, 24, 16, 10.1016/j.clnu.2004.08.004

Yang, 2008, Interleukin-6 stimulates lipolysis in porcine adipocytes, Endocrine, 33, 261, 10.1007/s12020-008-9085-7

Doerrler, 1992, Cytokines stimulate lipolysis and decrease lipoprotein lipase activity in cultured fat cells by a prostaglandin independent mechanism, Biochem. Biophys. Res. Commun, 186, 237, 10.1016/S0006-291X(05)80798-3

Hardardottir, 1994, Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters, Lymphokine Cytokine Res, 13, 161

Kawakami, 1987, Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells, J. Biochem, 10, 331, 10.1093/oxfordjournals.jbchem.a121917

Greenberg, 1992, Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes (a possible role for interleukin 6 in cancer cachexia), Cancer Res, 52, 4113

Rouzer, 1980, Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: Role of defective triglyceride removal, Mol. Biochem. Parasitol, 2, 31, 10.1016/0166-6851(80)90046-8

Jovinge, 1998, Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease, Metabolism, 47, 113, 10.1016/S0026-0495(98)90203-7

Feingold, 1989, Tumor necrosis factor stimulates hepatic lipid synthesis and secretion, Endocrinology, 124, 2336, 10.1210/endo-124-5-2336

Kawakami, 1981, Studies of endotoxin-induced decrease in lipoprotein lipase activity, J. Exp. Med, 154, 631, 10.1084/jem.154.3.631

Qin, 2008, Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling, Am. J. Physiol. Gastrointest. Liver Physiol, 294, G1120, 10.1152/ajpgi.00407.2007

Mohrschladt, 2000, Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy, Atherosclerosis, 148, 413, 10.1016/S0021-9150(99)00316-0

Jonkers, 2002, Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation (reversal with bezafibrate therapy in a randomized controlled trial), Am. J. Med, 112, 275, 10.1016/S0002-9343(01)01123-8

Nappo, 2002, Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients (role of fat and carbohydrate meals), J. Am. Coll. Cardiol, 39, 1145, 10.1016/S0735-1097(02)01741-2

Gussekloo, 2002, Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: The Leiden 85-Plus Study, Diabetes, 51, 1088, 10.2337/diabetes.51.4.1088

Grunfeld, 1991, Tumor necrosis factor-alpha, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells, Metabolism, 40, 894, 10.1016/0026-0495(91)90062-2

Gutierrez, 1999, Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects, Atherosclerosis, 146, 321, 10.1016/S0021-9150(99)00156-2

Skoog, 2002, Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men, Eur. Heart J, 23, 376, 10.1053/euhj.2001.2805

Mandecki, 2003, Hyperlipidaemias and serum cytokines in patients with coronary artery disease, Acta Cardiol, 58, 9, 10.2143/AC.58.1.2005253

Saez, 2012, Relation of high-density lipoprotein cholesterol and apoprotein A1 levels with presence and severity of coronary obstruction, ISRN Vasc. Med, 2012, 1, 10.5402/2012/451730

Ettinger, 1992, Effect of interleukin-1 alpha on lipoprotein lipids in cynomolgus monkeys (comparison to tumor necrosis factor), Biochim. Biophys. Acta, 1128, 186, 10.1016/0005-2760(92)90306-G

Ettinger, 1990, Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin (cholesterol acyltransferase in cynomolgus monkeys), J. Lipid Res, 31, 1099, 10.1016/S0022-2275(20)42750-6

Memon, 1993, Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice, Endocrinology, 132, 2246, 10.1210/endo.132.5.8477669

Feingold, 1995, Discordant regulation of proteins of cholesterol metabolism during the acute phase response, J. Lipid Res, 36, 1474, 10.1016/S0022-2275(20)39734-0

Ruan, 1998, Cytokine regulation of low-density lipoprotein receptor gene transcription in human mesangial cells, Nephrol. Dial. Transplant, 13, 1391, 10.1093/ndt/13.6.1391

Ruan, 2001, Dysregulation of LDL receptor under the influence of inflammatory cytokines (a new pathway for foam cell formation), Kidney Int, 60, 1716, 10.1046/j.1523-1755.2001.00025.x

Ruan, 2004, Regulation of lipoprotein trafficking in the kidney (role of inflammatory mediators and transcription factors), Biochem. Soc. Trans, 32, 88, 10.1042/bst0320088

Bartolome, 2007, Upregulation of apolipoprotein B secretion, but not lipid, by tumor necrosis factor-alpha in rat hepatocyte cultures in the absence of extracellular fatty acids, Ann. N. Y. Acad. Sci, 1096, 55, 10.1196/annals.1397.070

Homma, 2004, Predictors of atherosclerosis, J. Atheroscler. Thromb, 11, 265, 10.5551/jat.11.265

Crowl, 1991, Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response, J. Biol. Chem, 266, 2647, 10.1016/S0021-9258(18)52293-6

Kugiyama, 1999, Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease, Circulation, 100, 1280, 10.1161/01.CIR.100.12.1280

Chait, 2006, Serum amyloid A: The “other” inflammatory protein, Curr. Atheroscler. Rep, 8, 62, 10.1007/s11883-006-0066-0

Poitou, 2005, Serum amyloid A: Production by human white adipocyte and regulation by obesity and nutrition, Diabetologia, 48, 519, 10.1007/s00125-004-1654-6

Fasshauer, 2004, Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3–L1 adipocytes, J. Endocrinol, 183, 561, 10.1677/joe.1.05699

Yang, 2006, Acute-phase serum amyloid A: An inflammatory adipokine and potential link between obesity and its metabolic complications, PLoS Med, 3, e287, 10.1371/journal.pmed.0030287

Chen, 2008, Serum amyloid A protein regulates the expression of porcine genes related to lipid metabolism, J. Nutr, 138, 674, 10.1093/jn/138.4.674

Cai, 2005, Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake, J. Biol. Chem, 280, 2954, 10.1074/jbc.M411555200

Rigotti, 2003, The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues, Endocr. Rev, 24, 357, 10.1210/er.2001-0037

Lewis, 2004, Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice, Circulation, 110, 540, 10.1161/01.CIR.0000136819.93989.E1

Ouchi, 1999, Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin, Circulation, 100, 2473, 10.1161/01.CIR.100.25.2473

Matsubara, 2002, Decreased plasma adiponectin concentrations in women with dyslipidemia, J. Clin. Endocrinol. Metab, 87, 2764, 10.1210/jcem.87.6.8550

Okamoto, 2006, Adiponectin: A key adipocytokine in metabolic syndrome, Clin. Sci. (Lond.), 110, 267, 10.1042/CS20050182

Yamauchi, 2002, Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat. Med, 8, 1288, 10.1038/nm788

Berneis, 2002, Metabolic origins and clinical significance of LDL heterogeneity, J. Lipid Res, 43, 1363, 10.1194/jlr.R200004-JLR200

Schneider, 2005, Low plasma adiponectin levels are associated with increased hepatic lipase activityin vivo, Diabetes Care, 28, 2181, 10.2337/diacare.28.9.2181

Matsuura, 2007, Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver, Biochem. Biophys. Res. Commun, 358, 1091, 10.1016/j.bbrc.2007.05.040

Oku, 2007, Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver, FEBS Lett, 581, 5029, 10.1016/j.febslet.2007.09.038

Chang, 2012, Hypoadiponectinemia: A useful marker of dyslipidemia in women with polycystic ovary syndrome, Taiwan J. Obstet. Gynecol, 51, 583, 10.1016/j.tjog.2012.09.014

Angulo, 2002, Nonalcoholic fatty liver disease, N. Engl. J. Med, 346, 1221, 10.1056/NEJMra011775

Starley, 2010, Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection, Hepatology, 51, 1820, 10.1002/hep.23594

Lazo, 2008, The epidemiology of nonalcoholic fatty liver disease: A global perspective, Semin Liver Dis, 28, 339, 10.1055/s-0028-1091978

Tarantino, 2010, Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance, World J. Gastroenterol, 16, 4773, 10.3748/wjg.v16.i38.4773

Day, 1998, Steatohepatitis: A tale of two “hits”?, Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2

Tilg, 2010, Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis, Hepatology, 52, 1836, 10.1002/hep.24001

Polyzos, 2012, Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease, J. Clin. Gastroenterol, 46, 272, 10.1097/MCG.0b013e31824587e0

Bradbury, 2004, Lipid metabolism in hepatic steatosis, Clin. Liver Dis, 8, 639, 10.1016/j.cld.2004.04.005

Koteish, 2001, Animal models of steatosis, Semin. Liver Dis, 21, 89, 10.1055/s-2001-12932

Lambert, 2014, Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic Fatty liver disease, Gastroenterology, 146, 726, 10.1053/j.gastro.2013.11.049

Nielsen, 2004, Splanchnic lipolysis in human obesity, J. Clin. Investig, 113, 1582, 10.1172/JCI21047

Heilbronn, 2004, Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus, Int. J. Obes. Relat. Metab. Disord, 28, S12, 10.1038/sj.ijo.0802853

Roden, 2006, Mechanisms of disease: Hepatic steatosis in type 2 diabetes—Pathogenesis and clinical relevance, Nat. Clin. Pract. Endocrinol. Metab, 2, 335, 10.1038/ncpendmet0190

Montague, 2000, The perils of portliness: Causes and consequences of visceral adiposity, Diabetes, 49, 883, 10.2337/diabetes.49.6.883

Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J. Clin. Investig, 115, 1343, 10.1172/JCI23621

Parks, 2006, Thematic review series: Patient-oriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques, J. Lipid Res, 47, 1651, 10.1194/jlr.R600018-JLR200

Harrison, 2007, Benefits of lifestyle modification in NAFLD, Gut, 56, 1760, 10.1136/gut.2006.112094

Shklyaev, 2003, Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats, Proc. Natl. Acad. Sci. USA, 100, 14217, 10.1073/pnas.2333912100

Xu, 2003, The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J. Clin. Investig, 112, 91, 10.1172/JCI200317797

Schindhelm, 2006, Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease, Diabetes Metab. Res. Rev, 22, 437, 10.1002/dmrr.666

Masaki, 2004, Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice, Hepatology, 40, 177, 10.1002/hep.20282

Kamada, 2003, Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin, Gastroenterology, 125, 1796, 10.1053/j.gastro.2003.08.029

Hui, 2004, Beyond insulin resistance in NASH: TNF-alpha or adiponectin?, Hepatology, 40, 46, 10.1002/hep.20280

Botas, 2004, Adiponectin, hepatocellular dysfunction and insulin sensitivity, Clin. Endocrinol. (Oxf.), 60, 256, 10.1046/j.1365-2265.2004.01977.x

Targher, 2004, Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals, Clin. Endocrinol. (Oxf.), 61, 700, 10.1111/j.1365-2265.2004.02151.x

Kaser, 2005, Adiponectin and its receptors in non-alcoholic steatohepatitis, Gut, 54, 117, 10.1136/gut.2003.037010

Stefan, 2005, Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat, Diabetologia, 48, 2282, 10.1007/s00125-005-1948-3

Minokoshi, 2002, Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase, Nature, 415, 339, 10.1038/415339a

Kakuma, 2000, Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets, Proc. Natl. Acad. Sci. USA, 18, 8536, 10.1073/pnas.97.15.8536

Lee, 2002, PPAR alpha is necessary for the lipogenic action of hyperleptinemia on white adipose and liver tissue, Proc. Natl. Acad. Sci. USA, 99, 11848, 10.1073/pnas.182420899

Serin, 2003, Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver, J. Gastroenterol, 38, 471, 10.1007/s00535-002-1084-5

Poordad, 2004, The role of leptin in NAFLD contender or pretender?, J. Clin. Gastroenterol, 38, 841, 10.1097/00004836-200411000-00002

Tobe, 1999, Relationship between serum leptin and fatty liver in Japanese male adolescent university students, Am. J. Gastroenterol, 94, 3328, 10.1111/j.1572-0241.1999.01549.x

Marra, 2002, Leptin and liver fibrosis: A matter of fat, Gastroenterology, 122, 1529, 10.1053/gast.2002.33369

Cao, 2004, Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: Respective roles of the JAK/STAT and JAK-mediated H2O2-dependent MAPK pathways, J. Biol. Chem, 279, 4292, 10.1074/jbc.M308351200

Saxena, 2004, Leptin as a novel profibrogenic cytokine in hepatic stellate cells: Mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation, FASEB J, 18, 1612, 10.1096/fj.04-1847fje

Banerjee, 2003, Resistin: Molecular history and prognosis, J. Mol. Med, 81, 218, 10.1007/s00109-003-0428-9

Pagano, 2006, Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance, J. Clin. Endocrinol. Metab, 91, 1081, 10.1210/jc.2005-1056

Crespo, 2001, Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients, Hepatology, 34, 1158, 10.1053/jhep.2001.29628

Ding, 2004, Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury, J. Cell. Mol. Med, 8, 445, 10.1111/j.1582-4934.2004.tb00469.x

Manco, 2007, Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease, Am. J. Clin. Pathol, 127, 954, 10.1309/6VJ4DWGYDU0XYJ8Q

Sanal, 2008, The blind men see the elephant-the many faces of fatty liver disease, World J. Gastroenterol, 14, 831, 10.3748/wjg.14.831

Saleh, 1999, Regional specificity of ASP binding in human adipose tissue, Am. J. Physiol, 276, E815

Massiera, 2001, Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation, FASEB J, 15, 2727, 10.1096/fj.01-0457fje

Umemura, 1997, Plasma angiotensinogen concentrations in obese patients, Am. J. Hypertens, 10, 629, 10.1016/S0895-7061(97)00053-8

Dixon, 2003, Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese, J. Hepatol, 39, 967, 10.1016/S0168-8278(03)00459-8